These experiments evaluate the role of the Epstein-Barr virus (EBV) nuclear antigen leader protein (EBNA-LP) in B-lymphocyte growth transformation by using a recombinant EBV molecular genetic approach. Recombinant viruses encoding for a mutant EBNA-LP lacking the carboxy-terminal 45 amino acids were markedly impaired in their ability to transform primary B lymphocytes compared with EBNA-LP wild-type but otherwise isogenic recombinant viruses. This impairment was particularly evident when primary B lymphocytes were infected under conditions of limiting virus dilution. The impairment could be partially corrected by growth of the infected lymphocytes with fibroblast feeder layers or by cocultivation of primary B lymphocytes with relatively highly permissive mutant virus-infected cells. One of the five mutant recombinants recovered by growth of infected cells on fibroblast feeder cultures was a partial revertant which had a normal transforming phenotype. Several lymphoblastoid cell lines infected with the EBNA-LP mutant recombinant viruses had a high percentage of cells with bright cytoplasmic immunoglobulin staining, as is characteristic of cells undergoing plasmacytoid differentiation. Expression of the other EBV latent or lytic proteins and viral replication were not affected by the EBNA-LP mutations. Thus, the EBNA-LP mutant phenotype is not mediated by an effect on expression of another EBV gene. These data are most compatible with the hypothesis that EBNA-LP affects expression of a B-lymphocyte gene which is a mediator of cell growth or differentiation.
At least nine Epstein-Barr virus (EBV) genes are expressed in latent EBV infection of B lymphocytes (for a review, see reference 21) . Two of these genes encode proteins which are expressed earliest in EBV infection, EBV nuclear antigen 2 (EBNA-2) and EBNA leader protein (EBNA-LP) (2) . The EBNA-LP RNA contains a downstream EBNA-2 open reading frame, and both EBNA-LP and EBNA-2 can be expressed from this message (37, 47) . The EBNA-LP and EBNA-2 RNAs have multiple repeating exons from the EBV genome long internal repeat and three exons from the unique DNA downstream of the repeat. The repeating exons and the first two unique exons encode EBNA-LP and can translate EBNA-LP when one of the two possible acceptor sites for the splice between the first and second exons results in a translational initiation codon at the beginning of the EBNA-LP open reading frame (37) . The last exon encodes for EBNA-2 and efficiently translates EBNA-2 from those RNAs which do not translate EBNA-LP because of a splice between the first and second exons which does not result in a translational initiation codon (47) . EBNA RNAs expressed after the initial EBNA-LP and EBNA-2 RNAs still have the exons encoding EBNA-LP but sometimes are spliced from upstream of the EBNA-2 open reading frame to exons far downstream which encode EBNA-3A, EBNA-3B, EBNA-3C, or EBNA-1 (6-9, 37, 40) . After EBNA-LP and EBNA-2 expression, promoters are activated for RNAs which encode two integral latent membrane proteins (LMPs) (13, 18, 23) . The EBNAs and LMPs are likely to be mediators of the EBV latent infection state or B-LYMPHOCYTE TRANSFORMATION BY EBV LEADER PROTEIN 6827 (LCLs) (40a). However, a bulk culture of cells infected with this virus stock grew slowly on a fibroblast feeder layer for several months and eventually grew slowly off fibroblast feeder layers. Analyses of these cells were limited to a Southern blot, which confirmed that the cells were infected with a recombinant EBV containing an EBNA-LP deletion mutation, and an immunoblot, which demonstrated high level EBNA-2 expression in the cells. In similar experiments using an endpoint dilution clonal transformation assay, we had found that primary B lymphocytes infected with mutant recombinant EBV deleted for the last two EBNA-LP exons did not give rise to long-term LCLs. Since the mutant recombinant virus-infected cells in these latter experiments were plated without fibroblast feeder layers, we undertook a series of experiments to determine whether fibroblast feeder layers would support the growth of the mutant recombinant virus-infected cells. The virus mutants and their phenotypic effects on the growth and gene expression of infected primary cells were then characterized.
MATERIALS AND METHODS
Cell lines. The P3HR1 clone 16 (33) , W91 (26) , IB4 (22) , or recombinant EBV-transformed LCLs were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS). FS4 is a primary human foreskin fibroblast cell line (kindly provided by J. Vilcek, New York University). HH293 is a primary human placental fibroblast cell line (kindly provided by G. Miller, Yale University).
Plasmids. The Escherichia coli plasmid pWT, used to generate recombinant EBVs, was constructed by inserting an EBV DNA W91 BglII fragment (corresponding to B958 nucleotides 44,664 to 54,359) (5) into the BamHI site of the pHEBo plasmid (42) . To make pDl, the last two EBNA-LP exons were deleted from pWT by removing a 350-bp HpaIHindIll fragment. Plasmid pSl was constructed by polymerase chain reaction (PCR) mutagenesis (30) . Briefly, part of the EBV W91 BamHI Y fragment was PCR amplified by using primers corresponding to B958 nucleotides 47,744 to 47,788 and 48,284 to 48, 304 . The first primer contained a 3-bp mutation, changing the first codon of the EBNA-LP Y1 exon from CCA to a TGA stop codon and the second codon from CTA to GTA. The GTA mutation creates a new RsaI site which could readily identify mutant DNA. The second primer included an upstream 20-bp sequence that was not homologous to EBV DNA. The amplified fragment was gel purified and mixed with BamHI-Y DNA. Hybrids between the amplified mutant fragment and the BamHI-Y DNA were then amplified with a third primer corresponding to B958 nucleotides 47,337 to 47 ,357 and a fourth primer identical to the 20-nucleotide non-EBV sequence in the second primer. The resulting amplified fragment was digested with XhoI and HindIII, and the XhoI-HindIII fragment was used to replace the corresponding fragment of pWT, thus creating pSl. The plasmid pSVNaeIBamZ was constructed by inserting the 1.2-kb NaeI-BamHI fragment from the BamHI Z fragment of B958 EBV DNA into the BamHI site of the plasmid pSG5 (Stratagene). Plasmid p4IgLP(+) was constructed by subcloning a murine immunoglobulin M (IgM) heavy chain variable region promoter and enhancer from plasmid u/u-gpt (16) into pFR400 (39 Northern, Southern, and immunoblot analyses. EBNA-1, EBNA-2, EBNA-3, EBNA-LP, and early antigen expression were assayed by immunoblot with EBV-immune human sera. LMP1 and LMP2 were detected by immunoblot with the S12 monoclonal antibody (24) and with an affinitypurified rabbit serum (23), respectively. Immunoglobulin expression was assayed by immunoblot with rabbit antihuman IgM Fc antibody (Jackson Laboratories) and alkaline phosphatase-conjugated goat anti-human IgG (heavy and light chains) antibody (Protoblot). Immunoblots were done as described previously (2) . RNA was isolated for Northern blots by acid guanidinium phenol-chloroform extraction (10). RNA was size fractionated on a 1% formaldehyde agarose gel and was transferred to activated nylon membranes (GeneScreen Plus; New England Nuclear). The filters were hybridized with a 32P-labelled EBNA-LP cDNA. For Southern analysis, total cellular DNA digested with BamHI was size fractionated on an 0.8% agarose gel and was transferred to an activated nylon membrane (GeneScreen Plus; New England Nuclear). The filters were hybridized to a 32p_ labelled EBV B958 BamHI H fragment.
Immunofluorescence and flow cytometry. Indirect immunofluorescence studies (2) of EBV latent protein expression were done with an EBNA-LP affinity-purified human serum, an EBNA-2 monoclonal antibody (PE2) (50) , or an LMP1 monoclonal antibody (S12) (24 (31) , the L2 monoclonal antibody to the late glycoprotein gpllO, or the 2L10 monoclonal antibody to the late glycoprotein gp350 (43) . Flow cytometry (46) for cell surface antigen expression was done by using monoclonal antibodies to CD23 (EBVCS1 [36] ), CD10 (J5, kindly provided by J. Ritz [34] ), ICAM1 (R/R 1/1, kindly provided by T. Springer [35] ), LFA1 and LFA3 (TS1/22 and TS2/9, kindly provided by T. Springer [38] ), CD39 (AC2, kindly provided by M. Rowe [36] ), CD40 (EA-5, kindly provided by T. LeBien), and CD44 (20 Growth curves and dilution studies. Cells were grown to saturation, centrifuged, and resuspended at the desired concentrations in RPMI 1640 with 10% FCS. Cell growth was determined by hemocytometer count or measurement of tritiated thymidine uptake every other day over a 7-to 14-day period. Tritiated thymidine uptake was measured after the cells were pulsed for 16 h with 3H-thymidine (2 ,uCi/ml). In dilution studies, serial dilutions of EBNA-LP mutant or wild-type virus-transformed cells from the same donor cells were plated in microtiter wells. The cells were observed without additional feeding for the next (25, 27) . Restoration of the deleted DNA segment by homologous recombination with a transfected EBV DNA fragment can restore the ability of the virus to transform primary B lymphocytes into long-term LCLs (11, 17) . Transformationcompetent recombinant EBV can then be specifically and clonally recovered by endpoint dilution infection and plating of primary B lymphocytes (11) . Mutations can be made in the EBNA-LP-or EBNA-2-encoding exons in the transfected DNA fragment. The effect of the mutations on the ability of the resultant mutant recombinant EBV to growth transform lymphocytes can then be assessed.
In several initial experiments, transformation-competent EBV recombinants were recovered when P3HR1 cells were transfected with a wild-type EBV DNA fragment which encompassed the DNA for which P3HR1 is deleted as well as flanking DNA homologous to P3HR1 (Fig. 1) . In contrast, no transformation-competent recombinant virus was recovered after transfection of P3HR1 with an otherwise isogenic EBV DNA fragment deleted for the last two exons of EBNA-LP (Y1 and Y2 in Fig. 1 ). Since fibroblast feeder layers improve the transformation efficiency of EBV (41) , in three additional experiments, primary lymphocytes infected with virus stocks from P3HR1 cells transfected with the EBNA-LP-deleted DNA fragment were plated on fibroblast feeders. In these experiments, only one LCL was obtained (Fig. 1) . In contrast, three parallel transfections of P3HR1 with a control wild-type EBV DNA fragment resulted in approximately 20 LCLs per experiment, even in the absence of fibroblast feeder layers (Fig. 1 ).
Since the Y1 and Y2 exons are part of all EBNA RNAs, recombinant virus with an EBNA-LP deletion could be defective in transforming primary lymphocytes because of a cis effect of the deletion on EBNA RNA processing or because the deletion creates an unnatural fusion between the EBNA-LP open reading frame and another coding domain. Therefore, a second mutation in which the first Y1 codon was mutated to a TGA stop codon was evaluated (Fig. 1) . This mutation would truncate EBNA-LP at the same place as the deletion mutation but would avoid the cis effects of the deletion described above. A single base change was also made in the second Y1 codon, creating a new RsaI site, which could be used to identify cells transformed by EBV recombinants carrying this stop codon mutation. In three separate experiments plated on fibroblast feeder layers, virus stocks derived from transfection of P3HR1 with two independently derived stop codon mutant EBNA-LP DNA fragments gave rise to only four LCLs. All four were from one experiment in which virus stocks derived from transfection of P3HR1 with a wild-type DNA fragment resulted in 48 LCLs in the absence of fibroblast feeders (Fig. 1) .
LCLs transformed by EBNA-LP mutant recombinant viruses took longer to be macroscopically visible in microwells with fibroblast feeders than did LCLs transformed by the EBNA-LP wild-type recombinant viruses. After infection of primary B lymphocytes with wild-type recombinant virus, macroscopically visible growth was evident by 4 weeks in approximately 50% of those wells which subsequently yielded LCLs. The (17) . pWT, pDl, and pSl were derived from the EBV W91 strain. The band at 9.7 kb seen in some of the lanes corresponds to the EBV DNA BamHI Bi fragment, which has homology to the BamHl H fragment (12) . The S1.1 cell line was coinfected with nonrecombinant P3HRL.
quenced to be certain that they contained the stop codon. The stop codon mutant which grew at early passage without fibroblast feeders was a partial revertant. The TGA stop codon was now TCA so that this recombinant maintained the wild-type open reading frame and differed from the wild type only in having Ser-Val instead of Pro-Leu at the beginning of the Y1-encoded domain. The three other stop codon mutants had the expected TGA replacing the first Y1 codon. The wild-type, deletion, stop codon, and partially revertant recombinant viral genomes were designated WT, DI, S1, and Ml, respectively. The previously described deletion mutant (17) was designated D2.
Southern blots of BamHI digest of DNA from cell lines transformed by WT, Dl, D2, Si, and Ml recombinant EBV were hybridized with a BamHI-H probe and confirmed that homologous recombination had occurred between P3HR1 and the transfected EBV DNA (Fig. 2) . Parental P3HR1 EBV DNA has a small 4.1-kb BamHI H hybridizing fragment due to the EBNA-LP and EBNA-2 deletion, which includes all of the BamHI Y fragment and most of BamHI H fragment ( Fig. 1 and 2) . The transfected plasmid has a 17-kb BamHI H hybridizing fragment because it lacks the BamHI site downstream of the EBNA-2 exon (Fig. 1 ), and therefore its BamHI H hybridizing fragment includes the 12-kb pHEBo plasmid fused to 5 kb of the EBV BamHI H fragment. The EBV BamHI H DNA fragments in the WT-, Dl-, SI-, and Mi-transformed LCLs are approximately 6.6 kb, the same size as the BamHI H fragment in the cell line (W91) from which the original transfected EBV DNA fragment was derived (11) (Fig. 2) . The EBV BamHI H DNA fragment in the D2-transformed cell lines is 6.0 kb (Fig. 2) , identical in size to the BamHI H fragment in the cell line (B958) from which its original transfected EBV DNA fragment was obtained (17) . The difference in the sizes of BamHI H DNAs in the W91 and B958 cell lines is probably due to a difference in the number of copies of the internal repeat 2 DNA (12) . The band at 9.7 kb seen in some of the lanes corresponds to the BamHI Bi fragment of P3HR1, which is partially homologous to the BamHI H fragment (12) . The S1.1 (Fig. 2) (Fig. 3B and C ) and no differences in EBNA-2 and LMP1 expression by immunofluorescence (data not shown). Immunoblots for EBNA-3A, EBNA-3B, and EBNA-3C and LMP2A also did not show differences among mutant or wild-type recombinant virus-transformed LCLs (data not shown).
EBV replication in EBNA-LP mutant or wild-type virustransformed LCLs. A human antiserum with high levels of antibody to immediate-early, early, and late replication cycle viral proteins was used in immunoblot analysis of EBV replication in the mutant and wild-type virus-transformed cells. The LCL transformed by the Dl recombinant virus had higher levels of expression of immediate-early, early, and late viral replication cycle-associated proteins than cells from the same donor transformed by the WT recombinant virus (Fig. 3A) . The D2-transformed LCL also spontaneously expressed large amounts of these viral replication cycle-associated proteins. However, the two Si-transformed cell lines and the Ml cell line expressed few if any viral replication cycle-associated proteins. Immunofluorescence analysis of EBV replication in the mutant or wild-type virus-transformed LCLs was performed by using the same human antiserum used in the immunoblot analysis or by using the monoclonal antibodies BZ.1, R3, L2, and 2L10 against, respectively, Z immediate-early, BMRF1 14 clones from a wild-type recombinant virus passaged in parallel. The Mlvirus-transformed LCLs were transferred from the initial microtiter wells to 1.5-ml wells without fibroblast feeder layers and grew as readily as the wild-type recombinant virus-infected controls. Thus, the new deletion mutant recombinant virus-infected LCLs all required fibroblast feeders for survival through our expansion protocol (as described in Materials and Methods), whereas the Ml twoamino-acid substitution revertant and the wild-type control transformed cells did not require fibroblast feeders. At- tempts to passage the S1.1 and S1.2 mutant recombinant viruses, even with fibroblast feeder layers, were unsuccessful, although a WT recombinant virus from a cell line with a similarly low level of virus production passaged in parallel yielded multiple transformed cell wells. The difficulty in passaging the S1 recombinants is likely to be due to the combined effects of the low level (<0.1%) of spontaneous virus replication in the two original S1-transformed LCLs, the poor growth of the original S1-infected cell lines, which markedly restricted the number of cocultivation experiments which could be performed, and the Si mutation effect on primary lymphocyte growth transformation.
Immunoblot and immunofluorescence analyses of EBV gene expression in the LCLs infected with passaged recombinant virus revealed no consistent differences in EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, LMP1, or LMP2a expression by immunoblot (Fig. 3) , as was characteristic of the initial LCLs transformed by the Dl, D2, S1, and Ml recombinants. Although the initial Dl-and D2-transformed LCLs were more permissive for viral replication than were the initial WT-transformed LCLs, no difference in permissivity to viral replication was noted by immunofluorescence or immunoblot when LCLs into which the Dl, D2, and Ml viruses were passaged were compared with LCLs from the same donor into which WT virus was passaged (Fig. 3A and Table 1 ). Therefore, the higher level of permissivity to viral replication seen in the initial Dl-or D2-infected LCLs compared with that in the wild-typetransformed controls was probably due to cell-specific factors rather than to the EBNA-LP deletions.
The decreased transformation efficiency of the EBNA-LP deletion and stop codon mutant recombinant viruses was not due to a lower virus yield from the mutant virus-transformed cells. As noted above, these cells were at least as permissive for replicative cycle antigen expression by immunofluorescence and immunoblot. By electron microscopic analysis, virus morphogenesis and viral particle number in productively infected cells did not differ significantly between the deletion mutant and wild-type recombinant virus-transformed LCLs. To evaluate the relative amounts of virus and transforming activity in the EBNA-LP mutant versus wildtype virus-infected cells, virus replication and transforming activity were assayed in two Dl-and two WT recombinant virus-transformed cell lines which had been derived in parallel by infection of the same donor's lymphocytes. The two Dl-infected cell lines produced no transforming virus as assayed by cocultivation with primary B lymphocytes without fibroblast feeder layers. One to two percent of the cells in these mutant virus-infected LCLs were spontaneously permissive for virus replication by immunofluorescence and electron microscopic analysis. Both wild-type control virusinfected cells did produce transforming virus in the same assay when less than 0.1% of the cells in one cell line and 1% of the cells in the other cell line were spontaneously permissive for virus replication by immunofluorescence and electron microscopy. These data confirm that the EBNA-LP deletion mutant recombinant virus is less efficient at transformation than the wild-type virus.
The effect of EBNA-LP mutations on B-lymphocyte differentiation. Since plasmacytoid differentiation with increased cytoplasmic immunoglobulin expression has been associated with decreased B-lymphocyte replicative capacity (49), cytoplasmic immunoglobulin levels in the mutant and wild-type virus-transformed cell lines were compared. Most Dl-or D2-transformed cell lines and all Ml-and WT-transformed cell lines had bright cytoplasmic immunoglobulin fluorescence staining in less than 5% of the cells after several months in culture (Fig. 4) . However, two of nine Dltransformed, one of five D2-transformed, and two of two S1-transformed LCLs had bright cytoplasmic immunoglobulin staining in 10 to 40% of the cells, even after several months in culture (Fig. 4 (49) . In the EBNA-LP mutant virus-infected cell lines, the intensity of cytoplasmic immunoglobulin staining was also inversely correlated with the intensity of EBNA-2 staining by two-color immunofluorescence (data not shown). Table 1 were studied at least 6 months after EBV infection. Cells were cytocentrifuged, fixed in ethanol and acetic acid, and stained with a fluorescein-conjugated goat anti-human IgG (heavy and light chains). The percentages of mutant (black boxes) or wild-type (white boxes) recombinant virus-transformed cells with bright cytoplasmic immunoglobulin staining are shown. The lymphocyte donor for each of the mutant and wild-type cell lines is described in footnote a of Table 1. virus-transformed cell lines. This does not exclude the possibility of quantitative differences in cytokine production. Since IL-6 is an autocrine growth factor for EBVinfected cells (45) , IL-6 production by the Dl and WT1 recombinant virus-transformed cell lines was assayed more quantitatively by measuring the growth of the IL-6-dependent B9 cell line grown in the presence of supernatants from Dl-or WT1-infected cells. Both the deletion mutant and the wild-type virus-transformed cell lines made similarly low levels of IL-6. Further, 1.6 ng of recombinant IL-6 per ml (Genetics Institute) minimally enhanced the growth rate of the original Dl-transformed LCL (data not shown).
The effect of wild-type EBNA-LP expression in EBNA-LP deletion mutant recombinant virus-transformed cells. A positive selection expression plasmid for EBNA-LP was transfected into the D2-transformed LCL to evaluate the effects of wild-type EBNA-LP expression in this mutant recombinant virus-transformed LCL. Transfected cells were selected without fibroblast feeder layers. Three methotrexateresistant clones were obtained. All three clones had characteristic EBNA-LP nuclear immunofluorescence staining with an EBNA-LP affinity-purified human serum which does not react with the deleted EBNA-LPs. However, the intensity of the fluorescence staining was weaker than in wild-type recombinant-transformed LCLs. PCR amplification with primers specific for the transfected plasmid confirmed that the three clones contained the transfected plasmid. 45 amino acids of the EBNA-LP. The persistently poor growth of the LCLs transformed by the stop codon recombinants, even on fibroblast feeder layers, and their lack of permissivity to virus replication have so far restricted extensive cellular or molecular biologic analyses.
Although the last two exons of the EBNA-LP are important in primary B-lymphocyte growth transformation, they are not absolutely essential. Primary B lymphocytes infected with EBNA-LP mutant recombinant EBV infrequently could be recovered as LCLs when they were maintained on fibroblast feeder layers or when the primary B lymphocytes were cocultivated with a very productive deletion mutantvirus-infected LCL. Presumably, cell outgrowth under the latter conditions resulted from many simultaneously initiated transforming events. However, the growth of these infected primary cells could not be maintained without fibroblast feeder support when the cultures were initially expanded. Thus, the phenotype of the deletion of the last 45 amino acids of EBNA-LP was profoundly evident when primary B lymphocytes were infected in an endpoint dilution clonal transformation assay without fibroblast feeders by using recombinant virus from transfected P3HR1 cells, slightly less evident when the infected cells were plated with fibroblast feeders, and consistently evident when mutant virusinfected cells were initially expanded from outgrowth in 96-well microtiter plates to 24-well plates.
Although wild-type EBV infection readily causes indefinite B-lymphocyte proliferation without a stringent requirement for fibroblast feeders, fibroblast feeders improve transformation efficiency (41) . A likely hypothesis which could explain the fibroblast feeder effect in primary B-lymphocyte growth transformation by wild-type EBV is that fibroblasts provide growth factor(s) which positively affect the probability that any EBV-infected B lymphocyte will give rise to an LCL. The unusual dependence of EBNA-LP mutant recombinant EBV-infected cells on fibroblast feeders could be due to an adverse effect of the EBNA-LP mutation on the ability of the recombinant EBV to induce an autocrine growth factor pathway necessary for full B-lymphocyte growth transformation and complementation of the defect by fibroblast derived growth factors. Since IL-6 is a fibroblast factor which positively affects EBV-infected cell outgrowth (45), IL-6 production was evaluated in the EBNA-LP Dl mutant recombinant LCL. No difference in IL-6 production was detected between the Dl and WT1 recombinant virusinfected cell lines. Furthermore, recombinant IL-6 had little effect on EBNA-LP Dl recombinant virus-infected cell growth.
An alternative possibility is that the last two EBNA-LP exons could be more stringently required for the transformation of most B lymphocytes than they are for transformation of a less common B-cell type which can be transformed by the mutant recombinant EBV as long as the cells are initially supported by fibroblast feeders. Little is known about whether fibroblast feeder layers differentially facilitate the outgrowth of specific B-lymphocyte subsets after EBV infection. Small resting B lymphocytes more readily give rise to LCLs after infection with wild-type EBV (3), and EBVtransformed LCLs arise almost exclusively from those B lymphocytes which express surface CD23 after EBV infection (4, 44 
